HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Contrast Media

Subscribe to New Research on Contrast Media

Substances used to allow enhanced visualization of tissues.

Also Known As:

Contrast Agents; Contrast Materials; Radiocontrast Agent; Radiocontrast Agents; Radiocontrast Media; Agent, Radiocontrast; Agents, Contrast; Agents, Radiocontrast; Materials, Contrast; Media, Contrast; Media, Radiocontrast; Media, Radiopaque; Radiopaque Media

Networked: 4447 relevant articles (175 outcomes, 409 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Specialty Uses of Chemicals
  - Contrast Media: 4447

Experts

1.	Corot, Claire: 19 articles (12/2013 - 06/2002)
2.	Lu, Zheng-Rong: 16 articles (10/2013 - 01/2006)
3.	Robert, Philippe: 15 articles (12/2013 - 05/2002)
4.	Fayad, Zahi A: 14 articles (03/2013 - 11/2004)
5.	Mulder, Willem J M: 13 articles (08/2013 - 10/2007)
6.	Wickline, Samuel A: 12 articles (01/2015 - 02/2006)
7.	Thomsen, Henrik S: 12 articles (02/2013 - 10/2002)
8.	Ni, Yicheng: 11 articles (10/2015 - 02/2002)
9.	Lanza, Gregory M: 11 articles (01/2015 - 02/2006)
10.	Pietsch, Hubertus: 11 articles (02/2013 - 01/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2005 - "New and exciting research using highly specific and bright tumor-targeted fluorescence contrast agents is thrusting diagnostic endoscopy into a new era of "molecular endoscopy." Most studies reported to date have mainly focused on refining existing prototype instruments or continue on a basic research level, with the ultimate goal of improving sensitivity and specificity for colonic dysplasia, compared with the gold standard of histopathology. " 05/01/1994 - "It is concluded that iomeprol-200 and iopamidol-200 are safe and effective contrast media when used for carotid IA-DSA, an examination which proves useful not only for the diagnosis of vascular lesions, but also to best direct the management of patients scheduled for surgery of intracranial tumors." 08/10/2009 - "In addition, traditional contrast agents are not very effective in detecting primary metastatic tumors and cells due to a lack of specificity and sensitivity of the diagnostic tools, which limits their effectiveness. " 10/01/2010 - "As shown in multiple experimental and clinical studies an optimized use of high quality contrast media and the introduction of these functional MRI methods has improved the detection and delineation of CNS tumors. " 02/06/2014 - "The development of new and improved photothermal contrast agents for the successful treatment of cancer (or other diseases) via plasmonic photothermal therapy (PPTT) is a crucial part of the application of nanotechnology in medicine. "
2.	Neoplasm Metastasis (Metastasis) 08/07/2014 - "The development of ultrasound contrast agents with excellent tolerance and safety profiles has notably improved liver evaluation with ultrasound (US) for several applications, especially for the detection of metastases. " 01/01/2002 - "MRI with liver-specific contrast agents is superior to helical CT for detection of liver metastases. " 02/01/2007 - "For diagnosis, detection is improved, particularly for liver metastases with the development of cellular imaging and liver-specific contrast agents. " 09/01/1990 - "Particulate contrast agents for improved ultrasound detection of liver metastases." 09/01/2013 - "The purpose of this study was to compare different contrast agents for longitudinal liver and spleen imaging in a mouse model of liver metastasis. "
3.	Renal Insufficiency (Renal Failure) 04/01/2005 - "Significant reduction of the cortical perfusion (Qc = 0.057+/-0.030 ml/(s 100 g) to Qc = 0.030 +/- 0.017 ml/(s 100 g), P < 0.013) of the medullary perfusion (Qm = 0.023 +/- 0.018 ml/(s 100 g) to Qm = 0.011 +/- 0.006 ml/(s 100 g), P < 0.046) and of the accumulation of contrast media in the medulla (Qa = 0.005 +/- 0.003 ml/(s 100 g) to Qa = 0.0009 +/- 0.0008 ml/(s 100 g), P < 0.001) were found in presence of renal failure. " 03/01/2011 - "Contrast enhanced ultrasound (CEUS) has become an important diagnostic tool for hepatic, renal, pancreatic indications and several others due to: (a) an increasing rate of studies resulting in sufficient evidence especially in hepatic indications, (b) a rate of adverse events close to zero (1:10,000 in comparison to iodinated contrast agents from 1-12:100) enabling the application of CEUS in patients with severe renal insufficiency or thyroid gland autonomy, and (c) a reasonable price (depends on the country and influence of the health-care system [reimbursement]) and the dosage used. " 01/01/2011 - "In the present study these procedures were performed without using nephrotoxic contrast media in patients with preexisting renal insufficiency and iliofemoral artery disease. " 10/01/2008 - "According to current FDA guidelines for imaging patients with renal failure, use of CT with iodinated contrast media is preferred in patients with renal failure, over MR studies with Gd in patients with renal failure." 08/21/2007 - "Letter by Wetzels regarding article, "Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies"."
4.	Ischemia 01/01/2003 - "Experimental studies suggest that the pathogenesis of contrast media nephrotopathy is due to a combination of renal ischemia and direct tubular epithelial cell toxicity. " 08/01/1995 - "The present study was performed to examine the potential of diffusion-weighted (DW) imaging and dynamic first-passage bolus tracking of susceptibility contrast agents (perfusion imaging) for early in vivo evaluation of the effects of treatment with the free radical scavenger U74389G in a rat model of temporary focal ischemia. " 01/01/2014 - "Cytotoxicity of contrast media causes apoptosis of tubular cells with consequent formation of casts and worsening of ischemia. " 01/01/2014 - "The vasoconstriction of intrarenal vasculature is the main hemodynamic change induced by contrast media; the vasoconstriction is accompanied by a cascade of events leading to ischemia and reduction of glomerular filtration rate. " 01/01/2014 - "This paper describes the generation of PEGylated magnetoliposomes and demonstrates their feasibility as negative contrast agents in a liver ischemia-reperfusion rat model."
5.	Coronary Artery Disease (Coronary Atherosclerosis) 12/01/2008 - "With the growing number of contrast-enhanced procedures being performed for coronary artery disease management, the safety and efficacy of iodinated contrast media (CM) have come under increased scrutiny. " 09/01/2006 - "Although the application of intravenous contrast agents during stress echocardiography has been shown to improve diagnostic accuracy for detecting coronary artery disease, less information exists regarding its prognostic value. " 12/01/2005 - "Furthermore, the use of these contrast agents during stress not only improved the assessment of wall motion but also made possible the evaluation of myocardial perfusion, thereby increasing diagnostic accuracy for the detection of coronary artery disease." 01/01/1999 - "The use of such intravascular contrast agents show great promise for clinical applications for noninvasive detection of coronary artery disease in humans." 10/01/2015 - "Rapid technological innovation engenders faster sequences and new contrast agents whereby a more accurate study of the myocardium and coronary artery disease is possible. "

Related Drugs and Biologics

1.	Gadolinium
2.	ferric oxide (iron oxide)
3.	Iodine
4.	Gadolinium DTPA (Magnevist)
5.	Folic Acid (Vitamin M)
6.	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)
7.	Iohexol (Omnipaque)
8.	Ligands
9.	Biological Markers (Surrogate Marker)
10.	Liposomes (Liposome)

Related Therapies and Procedures

1.	Microbubbles
2.	Heterologous Transplantation (Xenotransplantation)
3.	Injections
4.	Angioplasty (Angioplasty, Transluminal)
5.	Catheters